Ladder Bio (formerly ThirdLaw Molecular)
Blue Bell
About Ladder Bio (formerly ThirdLaw Molecular)
Ladder Bio is a therapeutics company that develops synthetic, ladder-shaped compounds engineered for high specificity and stability. The platform combines rational molecular design with computational discovery to create therapeutics with the potency of biologics but the drug-like stability, oral bioavailability, and cell permeability of small molecules. Ladder Bio also sees applications for its Spiroligomer chemistry in diagnostics, where the high-affinity binding and synthetic stability can replace more variable biologics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $23.6M
- Funding stage: Seed
- Last round: Seed (Oct 2025)
- Website: ladderbio.com
Industries & Categories
Biotechnology, Health Diagnostics, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ladder-bio-formerly-thirdlaw-molecular-58382 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.